We asked if preventing stroke induced apoptotic cell death using a novel peptidomimetic drug that is an irreversible antagonist of the caspase-3/7 Cys163 catalytic active site would lead to improved outcomes following stroke. This evidence concerns the gene CASP3 and stroke disorder.